Javascript on your browser is not enabled.


TATA Capital Invests $4M in Indian Pharmaceutical Company Brinton Pharmaceuticals Ltd.

Investment will be used to expand into Pediatrics, Gynaecology and expand operations to 32 countries.

Brinton Pharmaceuticals Ltd, a leading Indian pharmaceutical company, announced today that TATA Capital Healthcare fund has invested approximately $4 million in the Company, acquiring a minority stake. Brinton has been providing superior healthcare products and services for various therapeutic segments, to meet the unmet medical needs of millions of people.

The investment will support the firm’s entry into newer areas such Pediatric and Gynaecology segments and expand international operations from presently 8 to 32 countries.

Speaking about this investment, Rahul Darda, Managing Director of Brinton Pharmaceuticals Ltd, India said “Dermatology and Cosmeceuticals are among the fastest growing therapeutic segments in Indian Pharmaceutical Market growing at an annual CAGR of 15%. A long-term impact in the field of Research & Development will make newer innovations in the field of dermatology possible and Brinton is at the cusp of this transformation. Brinton has taken a therapy-focused approach towards growth and we believe this partnership with a focused Healthcare fund with Tata Capital is a step towards furthering the company’s growth objectives.”

“We are proud to announce TATA Capital’s investment in Brinton Pharmaceuticals Ltd., within two years of the beginning of commercial operations. This investment is a testimony to the company’s robust and strong foundations. We are optimistic about the future and have a roadmap in place to cross INR 300 Cr in the dermatology segment by FY 2021.” said Vijey Christopher, Sr. Vice President, Brinton Pharmaceuticals Ltd.

“With its strong brand proposition, Brinton Pharmaceuticals is well-poised to make a dent in the Dermatology space and we believe this investment from Tata Capital will further strengthen its wings to aggressively pursue its growth strategies.” said Vijay Datt, founder and CEO Citadel Management Consulting who was exclusive advisor of the transaction.

Brinton Pharmaceuticals Ltd, India was founded in 2013 with the aim of filling the need for affordable, yet high quality pharmaceuticals with world class packaging. Its innovative products are developed by anticipating patient requirements, and in an eco-friendly manner. Within a year, it became one of the fastest growing companies in India in the dermatology segment, despite an already crowded and competitive market. The firm has launched 14 new brands in India.

Since its launch, Brinton Pharmaceuticals’ has witnessed rapid expansion, thanks to its superior customer service and global operational excellence. It has a field workforce of 400 in India, and also spread operations in eight countries majorly Francophone and West Africa, along with Nepal, Sri Lanka and Bangladesh.

As per AWACS, Brinton Pharmaceuticals is the fastest growing pharmaceutical company amongst newly launched companies in last 24 months in all therapeutic segments. Currently, five of Brinton’s brands are ranked in top 5 brands in India.

Headquartered in Pune, India, Brinton Pharmaceuticals has a global presence with registered offices in USA, UK & Ghana.

Tags assigned to this article:
tata capital Brinton Pharmaceuticals Ltd.

Around The World